Xixiang Gao

Dr. Xixiang Gao

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2020 in Regenerative Medicine
Verified
Journal Article
Open access
JGJolanta Gorecka
Jolanta Gorecka
XGXixiang Gao
Xixiang Gao
AFArash Fereydooni
Arash Fereydooni
Biraja DashBiraja Dash
Biraja Dash
JLJiesi Luo
Jiesi Luo
ADAlan Dardik
Alan Dardik
Aim: To assess the potential of human induced pluripotent stem cell-derived smooth muscle cells (hiPSC-SMC) to accelerate diabetic wound healing. Methods: hiPSC-SMC were embedded in 3D collagen sca... Graphical abstract

21 January 2021 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
YMYutaka Matsubara
Yutaka Matsubara
GKGathe Kiwan
Gathe Kiwan
JLJia Liu
Jia Liu
LGLuis Gonzalez
Luis Gonzalez
JLJohn Langford
John Langford
ADAlan Dardik
Alan Dardik
Objective: Arteriovenous fistulae (AVF) are the preferred vascular access for hemodialysis, but the primary success rate of AVF remains poor. Successful AVF maturation requires vascular wall thickening and outward remodeling. A key factor determining successful AVF maturation is inflammation that is characterized by accumulation of both T-cells and macrophages. We have previously shown that anti-inflammatory (M2) macrophages are critically important for vascular wall thickening during venous remodeling; therefore, regulation of macrophage accumulation may be an important mechanism promoting AVF maturation. Since CD4+ T-cells such as T-helper type 1 cells, T-helper type 2 cells, and regulatory T-cells can induce macrophage migration, proliferation, and polarization, we hypothesized that CD4+ T-cells regulate macrophage accumulation to promote AVF maturation. Approach and Results: In a mouse aortocaval fistula model, T-cells temporally precede macrophages in the remodeling AVF wall. CsA (cyclosporine A; 5 mg/kg, sq, daily) or vehicle (5% dimethyl sulfoxide) was administered to inhibit T-cell function during venous remodeling. CsA reduced the numbers of T-helper type 1 cells, T-helper type 2, and regulatory T-cells, as well as M1- and M2-macrophage accumulation in the wall of the remodeling fistula; these effects were associated with reduced vascular wall thickening and increased outward remodeling in wild-type mice. However, these effects were eliminated in nude mice, showing that the effects of CsA on macrophage accumulation and adaptive venous remodeling are T-cell-dependent. Conclusions: T-cells regulate macrophage accumulation in the maturing venous wall to control adaptive remodeling. Regulation of T-cells during AVF maturation may be a strategy that can improve AVF maturation. Graphic A graphic abstract is available for this article.

2 April 2021 in Cells
Verified
Journal Article
Open access
PDF file
XGXixiang Gao
Xixiang Gao
MGMingjie Gao
Mingjie Gao
JGJolanta Gorecka
Jolanta Gorecka
JLJohn Langford
John Langford
JLJia Liu
Jia Liu
ADAlan Dardik
Alan Dardik
Induced pluripotent stem cells (iPSC) represent an innovative, somatic cell-derived, easily obtained and renewable stem cell source without considerable ethical issues. iPSC and their derived cells may have enhanced therapeutic and translational potential compared with other stem cells. We previously showed that human iPSC-derived smooth muscle cells (hiPSC-SMC) promote angiogenesis and wound healing. Accordingly, we hypothesized that hiPSC-SMC may be a novel treatment for human patients with chronic limb-threatening ischemia who have no standard options for therapy. We determined the angiogenic potential of hiPSC-SMC in a murine hindlimb ischemia model. hiPSC-SMC were injected intramuscularly into nude mice after creation of hindlimb ischemia. Functional outcomes and perfusion were measured using standardized scores, laser Doppler imaging, microCT, histology and immunofluorescence. Functional outcomes and blood flow were improved in hiPSC-SMC-treated mice compared with controls (Tarlov score, p < 0.05; Faber score, p < 0.05; flow, p = 0.054). hiPSC-SMC-treated mice showed fewer gastrocnemius fibers (p < 0.0001), increased fiber area (p < 0.0001), and enhanced capillary density (p < 0.01); microCT showed more arterioles (<96 μm). hiPSC-SMC treatment was associated with fewer numbers of macrophages, decreased numbers of M1-type (p < 0.05) and increased numbers of M2-type macrophages (p < 0.0001). Vascular endothelial growth factor (VEGF) expression in ischemic limbs was significantly elevated with hiPSC-SMC treatment (p < 0.05), and inhibition of VEGFR-2 with SU5416 was associated with fewer capillaries in hiPSC-SMC-treated limbs (p < 0.0001). hiPSC-SMC promote VEGF-mediated angiogenesis, leading to improved hindlimb ischemia. Stem cell therapy using iPSC-derived cells may represent a novel and potentially translatable therapy for limb-threatening ischemia.

1 June 2011 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
XGXixiang Gao
Xixiang Gao
JZJian Zhang
Jian Zhang
BCBing Chen
Bing Chen
HYHengXi Yu
HengXi Yu
JLJianXin Li
JianXin Li
JHJian Han
Jian Han

12 July 2017 in Perfusion
Verified
Journal Article
Closed access
XGXixiang Gao
Xixiang Gao
LLLiQiang Li
LiQiang Li
YGYongQuan Gu
YongQuan Gu
LGLianRui Guo
LianRui Guo
SCShiJun Cui
ShiJun Cui
JZJian Zhang
Jian Zhang
Objective: To present our experience of the endovascular treatment of subclavian artery aneurysms (SAAs) and analyze the clinical manifestations, imaging findings and treatment outcomes. Methods: In this retrospective study, nine patients with SAAs underwent endovascular stent placement in our center between July 2011 and June 2016. Clinical features, imaging findings, treatment outcomes and follow-up results of these SAA patients were retrospectively analyzed. Results: Nine patients were diagnosed with SAAs by computer tomography angiography (CTA). Five patients underwent percutaneous endovascular stent placement in the subclavian artery. Three patients underwent endovascular repair of the SAAs with coil embolization and stent graft. One patient underwent stent graft implantation by the simultaneous kissing stent technique. Five patients had their symptoms relieved and thrombosis occurred in one case. The mean follow-up period was 17 months, ranging from 8 to 40 months. Conclusion: For patients with SAAs, endovascular treatment is a feasible choice, with a high success rate, few complications and good clinical outcomes.

1 January 2020 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
XGXixiang Gao
Xixiang Gao
JGJianming Guo
Jianming Guo
ZTZhu Tong
Zhu Tong
LGLianrui Guo
Lianrui Guo
JZJian Zhang
Jian Zhang
YGYongquan Gu
Yongquan Gu